These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31286005)

  • 21. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
    Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy.
    Rothlind JC; York MK; Carlson K; Luo P; Marks WJ; Weaver FM; Stern M; Follett K; Reda D;
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):622-9. PubMed ID: 25185211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
    Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
    J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex-specific effects of subthalamic nucleus stimulation on pain in Parkinson's disease.
    Khazen O; DiMarzio M; Platanitis K; Grimaudo HC; Hancu M; Shao MM; Staudt MD; Maguire L; Sukul VV; Durphy J; Hanspal EK; Adam O; Molho E; Pilitsis JG
    J Neurosurg; 2021 Aug; 135(2):629-636. PubMed ID: 33036000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease.
    Mueller K; Jech R; Růžička F; Holiga Š; Ballarini T; Bezdicek O; Möller HE; Vymazal J; Růžička E; Schroeter ML; Urgošík D
    Neuroimage Clin; 2018; 19():1025-1035. PubMed ID: 30035027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep brain stimulation for monogenic Parkinson's disease: a systematic review.
    Kuusimäki T; Korpela J; Pekkonen E; Martikainen MH; Antonini A; Kaasinen V
    J Neurol; 2020 Apr; 267(4):883-897. PubMed ID: 30659355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pallidal Deep-Brain Stimulation Disrupts Pallidal Beta Oscillations and Coherence with Primary Motor Cortex in Parkinson's Disease.
    Wang DD; de Hemptinne C; Miocinovic S; Ostrem JL; Galifianakis NB; San Luciano M; Starr PA
    J Neurosci; 2018 May; 38(19):4556-4568. PubMed ID: 29661966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of second-sided deep brain stimulation for Parkinson's disease.
    Golubovsky JL; Li H; Momin A; Shao J; Lee MY; Frizon LA; Hogue O; Walter B; Machado AG; Nagel SJ
    J Neurosurg; 2021 Feb; 134(2):386-392. PubMed ID: 32059181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials.
    Tan ZG; Zhou Q; Huang T; Jiang Y
    Clin Interv Aging; 2016; 11():777-86. PubMed ID: 27382262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson's disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome.
    van Horne CG; Quintero JE; Slevin JT; Anderson-Mooney A; Gurwell JA; Welleford AS; Lamm JR; Wagner RP; Gerhardt GA
    J Neurosurg; 2018 Dec; 129(6):1550-1561. PubMed ID: 29451447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. King's Parkinson's Disease Pain Scale for Assessment of Pain Relief Following Deep Brain Stimulation for Parkinson's Disease.
    DiMarzio M; Pilitsis JG; Gee L; Peng S; Prusik J; Durphy J; Ramirez-Zamora A; Hanspal E; Molho E; McCallum SE
    Neuromodulation; 2018 Aug; 21(6):617-622. PubMed ID: 29608802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.
    Sayad M; Zouambia M; Chaouch M; Ferrat F; Nebbal M; Bendini M; Lesage S; Brice A; Brahim Errahmani M; Asselah B
    BMC Neurosci; 2016 Feb; 17():6. PubMed ID: 26831335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Pallidal and Subthalamic Deep Brain Stimulation on Urologic Function in Parkinson's Disease.
    Mock S; Osborn DJ; Brown ET; Stuart Reynolds W; Turchan M; Pallavaram S; Rodriguez W; Dmochowski R; Tolleson CM
    Neuromodulation; 2016 Oct; 19(7):717-723. PubMed ID: 27172446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should we offer deep brain stimulation to Parkinson's disease patients with GBA mutations?
    Artusi CA; Lopiano L
    Front Neurol; 2023; 14():1158977. PubMed ID: 37122287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do patient's get angrier following STN, GPi, and thalamic deep brain stimulation.
    Burdick AP; Foote KD; Wu S; Bowers D; Zeilman P; Jacobson CE; Ward HE; Okun MS
    Neuroimage; 2011 Jan; 54 Suppl 1():S227-32. PubMed ID: 20932923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revisiting the L-Dopa Response as a Predictor of Motor Outcomes After Deep Brain Stimulation in Parkinson's Disease.
    Lin Z; Zhang X; Wang L; Zhang Y; Zhou H; Sun Q; Sun B; Huang P; Li D
    Front Hum Neurosci; 2021; 15():604433. PubMed ID: 33613209
    [No Abstract]   [Full Text] [Related]  

  • 38. Eight-year follow-up outcome of subthalamic deep brain stimulation for Parkinson's disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity.
    Jiang L; Chen W; Guo Q; Yang C; Gu J; Xian W; Liu Y; Zheng Y; Ye J; Xu S; Hu Y; Wu L; Chen J; Qian H; Fu X; Liu J; Chen L
    CNS Neurosci Ther; 2021 Nov; 27(11):1366-1373. PubMed ID: 34350691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Awake vs. Asleep Surgery for Subthalamic Deep Brain Stimulation in Parkinson's Disease.
    Blasberg F; Wojtecki L; Elben S; Slotty PJ; Vesper J; Schnitzler A; Groiss SJ
    Neuromodulation; 2018 Aug; 21(6):541-547. PubMed ID: 29532560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
    Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
    Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.